Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

akorn - nedocromil sodium (unii: et8if4ks1t) (nedocromil - unii:0b535e0bn0) - nedocromil sodium 20 mg in 1 ml - nedocromil sodium ophthalmic solution is indicated for the treatment of itching associated with allergic conjunctivitis. nedocromil sodium ophthalmic solution is contraindicated in those patients who have shown hypersensitivity to nedocromil sodium or to any of the other ingredients.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

akorn - levocarnitine (unii: 0g389fzz9m) (levocarnitine - unii:0g389fzz9m) - levocarnitine 1 g in 10 ml - levocarnitine is indicated in the treatment of primary systemic carnitine deficiency. in the reported cases, the clinical presentation consisted of recurrent episodes of reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. associated symptoms included hypotonia, muscle weakness and failure to thrive. a diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see clinical pharmacology ). in some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. levocarnitine is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency. none known.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

oak pharmaceuticals, inc. (subsidiary of akorn, inc.) - benztropine mesylate (unii: wmj8tl7510) (benztropine - unii:1nhl2j4x8k) - benztropine mesylate 1 mg in 1 ml - for use as an adjunct in the therapy of all forms of parkinsonism (see dosage and administration). useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see precautions) due to neuroleptic drugs (e.g., phenothiazines). hypersensitivity to any component of cogentin injection. because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

akorn - lactulose (unii: 9u7d5qh5ae) (lactulose - unii:9u7d5qh5ae) - lactulose 10 g in 15 ml - for the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. controlled studies have shown that lactulose solution therapy reduced the blood ammonia levels by 25-50%; this is generally paralleled by an improvement in the patients’ mental state and by an improvement in eeg patterns. the clinical response has been observed in about 75% of the patients, which is at least as satisfactory as that resulting from neomycin therapy. an increase in patients’ protein tolerance is also frequently observed with lactulose therapy. in the treatment of chronic portal-systemic encephalopathy, lactulose has been given for over 2 years in controlled studies. since lactulose solution contains galactose (less than 1.6 g/15 ml), it is contraindicated in patients who require a low galactose diet.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

oak pharmaceuticals, inc. (subsidiary of akorn, inc.) - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride 0.5 mg in 18 ml - xylocaine (lidocaine hcl) 2% jelly is indicated for prevention and control of pain in procedures involving the male and female urethra, for topical treatment of painful urethritis, and as an anesthetic lubricant for endotracheal intubation (oral and nasal). lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to other components of xylocaine 2% jelly.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

akorn - lactulose (unii: 9u7d5qh5ae) (lactulose - unii:9u7d5qh5ae) - for the treatment of constipation. in patients with a history of chronic constipation, lactulose solution therapy increases the number of bowel movements per day and the number of days on which bowel movements occur. since lactulose solution contains galactose (less than 1.6 g/15 ml), it is contraindicated in patients who require a low galactose diet.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

akorn - loteprednol etabonate (unii: yeh1ez96k6) (loteprednol - unii:z8cbu6kr16) - loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. loteprednol etabonate is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. the incidence of patients with clinically significant increases in iop (≥10 mmhg) was 1% with loteprednol etabonate and 6% with prednisolone acetate 1%. loteprednol etabonate should not be used in patients who require a more potent corticosteroid for this indi

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

akorn - loteprednol etabonate (unii: yeh1ez96k6) (loteprednol - unii:z8cbu6kr16) - loteprednol etabonate ophthalmic gel is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. loteprednol etabonate ophthalmic gel is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, in mycobacterial infection of the eye and fungal diseases of ocular structures. risk summary there are no adequate and well-controlled studies with loteprednol etabonate in pregnant women. loteprednol etabonate produced teratogenicity at clinically relevant doses in the rabbit and rat when administered orally during pregnancy. loteprednol etabonate produced malformations when administered orally to pregnant rabbits at doses ≥ 1.2 times the recommended human ophthalmic dose (rhod) and to pregnant rats at doses ≥ 30 times the rhod. in pregnant rats receiving oral doses of loteprednol etabonate during the period equivalent to the last trimester of pregnancy through

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

akorn - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 25 mg in 1 ml - levofloxacin injection is indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae. adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1) ]. levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible staphyloc

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

akorn - trihexyphenidyl hydrochloride (unii: ao61g82577) (trihexyphenidyl - unii:6rc5v8b7po) - trihexyphenidyl hydrochloride 2 mg in 5 ml - trihexyphenidyl is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). it is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones. trihexyphenidyl is contraindicated in patients with hypersensitivity to trihexyphenidyl or to any of the other ingredients. trihexyphenidyl is also contraindicated in patients with narrow angle glaucoma. blindness after long-term use due to narrow angle glaucoma has been reported. although trihexyphenidyl is not classified as a controlled substance, the possibility of abuse should be borne in mind due to its stimulant and euphoriant properties.